30 January - 5 February 2016
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Fingolimod for PPMS trial unsuccessful
Company pulls out of female hormone treatment
A drug development company that was working on the development of Trimesta (estriol) as a treatment for relapsing remitting MS has withdrawn from the project. Their decision was based on an analysis of the results of the trial of the drug in combination with Copaxone, which it felt wasn't significantly better than Copaxone alone. The trial results were reported in December
Source: PR Newswire
MS Trust link: Hormones
Tysabri v fingolimod
An observational study in France found that at both one year and two years of treatment, people on Tysabri had a lower relapse rate than those taking fingolimod. They also showed fewer new lesions on MRI. There was no difference between the drugs on measures of the change in disability measured by EDSS. [The story uses the word 'more' in the third paragraph when presumably it should say 'fewer']
Source: News Medical
MS Trust link: MS Decisions
Indicators of risk of primary progressive MS
A US study looked at people with radiologically isolated syndrome (areas of damage visible on MRI but no symptoms and not yet diagnosed with MS). About 12% went on to develop primary progressive MS. These people were more likely to be men, older and to have lesions in the spinal cord
Source: National MS Society (USA)
MS Trust link: Primary progressive MS